SV40 large T antigen

Proto-oncogene derived from polyomavirus SV40

SV40 large T antigen

SV40 T helicase domain hexamer, Simian virus.

Identifiers
Organism| Simian virus 40
Symbol| ?
UniProt| P03070
| Search for

Structures| Swiss-model
Domains| InterPro

SV40 large T antigen (Simian Vacuolating Virus 40 TAg) is a hexamer protein that is a dominant-acting oncoprotein derived from the polyomavirus SV40. TAg is capable of inducing malignant transformation of a variety of cell types. The transforming activity of TAg is due in large part to its perturbation of the retinoblastoma (pRb)[1] and p53 tumor suppressor proteins.[2] In addition, TAg binds to several other cellular factors, including the transcriptional co-activators p300 and CBP, which may contribute to its transformation function.[3] Similar proteins from related viruses are known as large tumor antigen in general.

TAg is a product of an early gene transcribed during viral infection by SV40, and is involved in viral genome replication and regulation of host cell cycle. SV40 is a double-stranded, circular DNA virus belonging to the Polyomaviridae (earlier Papovavirus) family, Orthopolyomavirus genus. Polyomaviruses infect a wide variety of vertebrates and cause solid tumours at multiple sites. SV40 was isolated by Sweet and Maurice Hilleman in 1960 in primary monkey kidney cell cultures being used to grow Sabin OPV.[4]

## Domains

[edit]

The TAg has a CUL7-binding domain, a TP53-binding domain, a Zinc finger, and a Superfamily 3 ATPase/Helicase domain. It has two motifs, one for nuclear localization signal, the other being the LXCXE motif.[5]

## Mechanism

[edit]

After entering the cell, the viral genes are transcribed by host cell RNA polymerase II to produce early mRNAs. Because of the relative simplicity of the genome, polyomaviruses are heavily dependent on the cell for transcription and genome replication. The cis-acting regulatory element surrounding the origin of replication directs transcription, and T-antigen directs transcription and replication.

SV40 DNA replication is initiated by binding of large T-antigen to the origin region of the genome. The function of T-antigen is controlled by phosphorylation, which attenuates the binding to the SV40 origin. Protein-protein interactions between T-antigen and DNA polymerase-alpha directly stimulate replication of the virus genome.

T-antigen also binds and inactivates tumor suppressor proteins (p53, p105-Rb). This causes the cells to leave G1 phase and enter into S phase, which promotes DNA replication.

The SV40 genome is very small and does not encode all the information necessary for DNA replication. Therefore, it is essential for the host cell to enter S phase, when cell DNA and the viral genome are replicated together. Therefore, in addition to increasing transcription, another function of T-antigen is to alter the cellular environment to permit virus genome replication.

## Nuclear localization signal

[edit]

The SV40 large T-antigen has been used as a model protein to study nuclear localization signals (NLSs).[6] It is imported into the nucleus by its interaction with importin α.[7] The NLS sequence is PKKKRKV.[6]

## Interaction with pRb via the LXCXE motif

[edit]

SV40 large TAg, other polyomavirus large T antigens, adenovirus E1a proteins, and oncogenic human papillomavirus E7 proteins share a structural motif that encodes a high-affinity pRb-binding domain.[8][9] A diagnostic pattern for a high-affinity pRb-binding domain was refined using an artificial intelligence pattern-induction program running on a massively parallel supercomputer (Connection Machine-2).[9] The motif is characterized by an Asp, Asn or Thr residue followed by three invariant amino acids, interspersed with non-conserved amino acids (designated by x, where x cannot be a Lys or Arg residue).[9] A negatively charged region frequently follows carboxy-terminal to the pRb-binding domain.[9]

{Asp/Asn/Thr} – Leu – x – Cys – x – Glu – x – ... {negatively charged region}

Hydrophobic and electrostatic properties are highly conserved in this motif. For example, a local hydrophobicity maximum occurs in the vicinity of the invariant Leu residue.[9] A net negative charge occurs within 3 residues amino-terminal to the invariant Leu residue; furthermore, positively charged amino acids (Lys or Arg) are not found within the Leu – x – Cys – x – Glu sequence, nor in the positions immediately flanking this sequence.[9] The pRb-binding motif and negatively charged region match to a segment of SV40 TAg beginning at residue 102 and ending at residue 115 as shown below:

– Asn – Leu – Phe – Cys – Ser – Glu – Glu – Met – Pro – Ser – Ser – Asp – Asp – Glu –

Functional studies of TAg proteins bearing mutations within this segment (amino acid positions 106 to 114, inclusive) demonstrate that certain deleterious mutations abolish malignant transforming activity.[10] For example, mutation of the invariant Glu at position 107 to Lys-107 completely abolishes transforming activity.[10] Deleterious mutations within this segment (amino acid positions 105 to 114, inclusive) also impair binding of the mutant TAg protein species to pRb,[1] implying a correlation between transforming activity and the ability of TAg to bind pRb.[1] A detailed computerized bioinformatics analysis,[9] as well as an x-ray crystallography study,[11] have demonstrated the biophysical basis for the interaction between this region of TAg and pRb. TAg residues 103 to 109 form an extended loop structure that binds tightly in a surface groove of pRb.[11] In the crystal structure, Leu-103 is positioned so that it makes van der Waals contacts with the hydrophobic side chains of Val-714 and Leu-769 in pRb.[11] A number of hydrogen bonds also stabilize the TAg–pRb complex.[11] For example, the side chain of Glu-107 forms hydrogen bonds by accepting hydrogens from the main chain amide groups of Phe-721 and Lys-722 in pRb.[11] The mutation of Glu-107 to Lys-107 is expected to result in loss of these hydrogen bonds.[11] Furthermore, the side chain of Lys-107 would likely have energetically unfavorable interactions with the amide of Phe-721 or Lys-722,[11] destabilizing the complex.

Strong experimental evidence confirms that positively charged amino acids (Lys or Arg) significantly weaken the binding interaction with pRB when positioned in the vicinity of the Leu – x – Cys – x – Glu sequence.[12] This is likely due to the fact that the binding surface on pRb features six lysine residues, which will tend to repel positive residues within or flanking the Leu – x – Cys – x – Glu sequence.[12]

Of note, the highest-risk oncogenic human papillomavirus (HPV) strains (16, 18, 31, 45) encode E7 proteins featuring high-affinity pRb-binding domains which match the diagnostic pattern given above.[9]

## References

[edit]

1. ^ a b c DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, Lee WH, Marsillo E, Paucha E, Livingston DM (15 July 1988). "SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene". Cell. 54 (2): 275–83\. doi:10.1016/0092-8674(88)90559-4. PMID 2839300. S2CID 37600468.
2. ^ Ahuja D, Sáenz-Robles MT, Pipas JM (2005). "SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation". Oncogene. 24 (52): 7729–45\. doi:10.1038/sj.onc.1209046. PMID 16299533.
3. ^ Ali SH, DeCaprio JA (2001). "Cellular transformation by SV40 large T antigen: interaction with host proteins". Semin Cancer Biol 11 (1): 15–23. Archived 2004-01-19 at the Wayback Machine
4. ^ Sweet BH, Hilleman MR (November 1960). "The vacuolating virus, S.V. 40". Proc. Soc. Exp. Biol. Med. 105 (2): 420–427\. doi:10.3181/00379727-105-26128. PMID 13774265. S2CID 38744505.
5. ^ P03070; InterPro view for P03070.
6. ^ a b Dingwall C, Laskey RA (December 1991). "Nuclear targeting sequences – a consensus?". Trends Biochem. Sci. 16 (12): 478–81\. doi:10.1016/0968-0004(91)90184-W. PMID 1664152.
7. ^ Fontes MR, Teh T, Kobe B (April 2000). "Structural basis of recognition of monopartite and bipartite nuclear localization sequences by mammalian importin-alpha". J. Mol. Biol. 297 (5): 1183–94\. doi:10.1006/jmbi.2000.3642. PMID 10764582.
8. ^ Figge J, Smith TF (14 July 1988). "Cell division sequence motif". Nature. 334 (6178): 109. doi:10.1038/334109a0. PMID 3290690.
9. ^ a b c d e f g h Figge J, Breese K, Vajda S, Zhu QL, Eisele L, Andersen TT, MacColl R, Friedrich T, Smith TF (February 1993). "The binding domain structure of retinoblastoma-binding proteins". Protein Science. 2 (2): 155–64\. doi:10.1002/pro.5560020204. PMC 2142352. PMID 8382993.
10. ^ a b Chen S, Paucha E (July 1990). "Identification of a region of simian virus 40 large T antigen required for cell transformation". Journal of Virology. 64 (7): 3350–7\. doi:10.1128/JVI.64.7.3350-3357.1990. PMC 249578. PMID 2161944.
11. ^ a b c d e f g Kim HY, Ahn BY, Cho Y (15 January 2001). "Structural basis for the inactivation of retinoblastoma tumor suppressor by SV40 large T antigen". The EMBO Journal. 20 (1–2): 295–304\. doi:10.1093/emboj/20.1.295. PMC 140208. PMID 11226179.1–2&rft.pages=295-304&rft.date=2001-01-15&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC140208#id-name=PMC&rft_id=info:pmid/11226179&rft_id=info:doi/10.1093/emboj/20.1.295&rft.aulast=Kim&rft.aufirst=HY&rft.au=Ahn,+BY&rft.au=Cho,+Y&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC140208&rfr_id=info:sid/en.wikipedia.org:SV40+large+T+antigen" class="Z3988">
12. ^ a b Singh M, Krajewski M, Mikolajka A, Holak TA (11 November 2005). "Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences". The Journal of Biological Chemistry. 280 (45): 37868–76\. doi:10.1074/jbc.M504877200. PMID 16118215.

* v
* t
* e

Viral proteins (early and late)

DNA|

| linear ds-DNA
(Duplodnaviria,
Varidnaviria)|

| Herpes simplex|

| VSPs:|

| capsid:|

* HHV capsid portal protein
* Herpesvirus glycoprotein B

|

VNPs:|

* vmw65
* ICP8
* ICP34.5
* ICP47

Vaccinia|

| VNPs:|

* B13R

|

Adenoviridae|

| VNPs:|

* E1A
* E1B

|

circular ds-DNA
(Duplodnaviria,
Varidnaviria?)|

| Epstein–Barr|

| VSPs:|

* LMP-1
* LMP-2

|

VNPs:|

* EBNA-1
* EBNA-2
* EBNA-3

ncRNA:|

* EBER

Baculoviridae|

| VNPs:|

* Early 35 kDa protein

|

other
(Riboviria,
Monodnaviria)|

| Polyomaviridae
(SV40, MPyV, MCPyV, HaPyV)
(non-enveloped circular ds-DNA)|

| VSPs:|

| capsid:|

* VP1
* VP2 and VP3

|

VNPs:|

| oncoprotein:|

* STag
* MTag
* LTag (SV40 Tag)

|

* Agnoprotein

Hepatitis B
(circular partially ds-DNA)|

| VSPs:|

* HBsAg
* HBcAg

* HBeAg

|

VNPs:|

* HBx
* Hepatitis B virus DNA polymerase

RNA|

| ds-RNA
(Riboviria)|

| Rotavirus
(Duplornaviricota)|

| VNPs:|

* NSP1
* NSP2
* NSP3
* NSP4
* NSP5
* NSP6

|

Rhinov., Polio, Hep A,
etc. (Pisuviricota)|

| VNPs:|

* VPg

|

ss-RNA
positive-sense
(Riboviria)|

| Hepatitis C
(Kitrinoviricota)|

| VSPs:|

* viral envelope
* E1
* E2

|

VNPs:|

* P7
* NS2
* NS3
* NS4A
* NS4B
* NS5A
* NS5B

SARS-CoV-2
(Pisuviricota)|

| VSPs:|

* viral envelope
* Spike
* Envelope
* Membrane
* Nucleocapsid

|

VNPs:|

* ORF1ab
* 3C-like protease (NS5)
* ORF3a
* ORF3b
* ORF3c
* ORF3d
* ORF6
* ORF7a
* ORF7b
* ORF8
* ORF9b

ss-RNA
negative-sense
(Negarnaviricota)|

| Influenza virus|

| VSPs:|

| capsid:|

* matrix protein
* M1 protein
* viral envelope
* M2 protein

|

glycoprotein:|

* Influenza hemagglutinin
* Neuraminidase
* HA-tag

VNPs:|

* NS1

Parainfluenza|

| VSPs:|

| glycoprotein:|

* Parainfluenza hemagglutinin-neuraminidase

|

Mumps|

| VSPs:|

| glycoprotein:|

* Mumps hemagglutinin-neuraminidase

|

Measles|

| VSPs:|

| glycoprotein:|

* Measles hemagglutinin

|

RSV|

| VSPs:|

| glycoprotein:|

* Respiratory syncytial virus G protein

|

Zaire ebolavirus|

| VSPs:|

| capsid:|

* matrix protein
* VP40
* VP24

|

Indiana vesiculovirus|

| VSPs:|

| capsid:|

* matrix protein
* Vesiculovirus matrix proteins

|

RT|

| Structure and genome of HIV|

| VSPs:|

* gag
* p24
* pol
* Integrase
* Reverse transcriptase
* HIV-1 protease
* env
* gp120
* gp41

|

VRAPs:|

* transactivators
* Tat
* Rev
* Vpr
* Nef
* Vif
* Vpu or Vpx

Multiple

*     * Rous sarcoma virus
* murine leukemia virus

| Fusion protein|

| oncoprotein:|

* Gag-onc fusion protein

|

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template